Researchers have launched an early-stage clinical trial to evaluate a vaccine aimed at Alzheimer's disease.
Alzheimer's is a progressive condition that gradually erodes memory, reasoning and daily independence.
A central suspect in the disease is tau, a protein that builds up abnormally inside brain cells.
The experimental vaccine is engineered to prompt the immune system to clear away this harmful tau.
In this first phase, the priority is not to prove effectiveness but to confirm that the treatment is safe over roughly a year.
Researchers stress that the work remains preliminary and that any approved therapy is still far away.
Nevertheless, the trial reflects a dramatic surge in Alzheimer's research funding and scientific attention.
For millions of families affected by the disease, such efforts represent a genuine source of hope.